On Friday, Voyager Therapeutics Inc (NASDAQ: VYGR) opened lower -7.21% from the last session, before settling in for the closing price of $3.19. Price fluctuations for VYGR have ranged from $2.64 to $9.21 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 1.48% over the past five years. Company’s average yearly earnings per share was noted -86.98% at the time writing. With a float of $45.19 million, this company’s outstanding shares have now reached $55.21 million.
Let’s look at the performance matrix of the company that is accounted for 172 employees. In terms of profitability, gross margin is 48.55%, operating margin of -152.03%, and the pretax margin is -125.46%.
Voyager Therapeutics Inc (VYGR) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Voyager Therapeutics Inc is 18.69%, while institutional ownership is 63.39%. The most recent insider transaction that took place on Apr 02 ’25, was worth 34,595. In this transaction Chief Medical Officer of this company sold 10,086 shares at a rate of $3.43, taking the stock ownership to the 157,914 shares. Before that another transaction happened on Apr 02 ’25, when Company’s President and CEO sold 10,885 for $3.43, making the entire transaction worth $37,336. This insider now owns 430,931 shares in total.
Voyager Therapeutics Inc (VYGR) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -86.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -12.48% during the next five years compared to 1.48% growth over the previous five years of trading.
Voyager Therapeutics Inc (NASDAQ: VYGR) Trading Performance Indicators
Check out the current performance indicators for Voyager Therapeutics Inc (VYGR). In the past quarter, the stock posted a quick ratio of 6.10. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.46, a number that is poised to hit -0.53 in the next quarter and is forecasted to reach -1.33 in one year’s time.
Technical Analysis of Voyager Therapeutics Inc (VYGR)
Voyager Therapeutics Inc (NASDAQ: VYGR) saw its 5-day average volume 0.93 million, a positive change from its year-to-date volume of 0.5 million. As of the previous 9 days, the stock’s Stochastic %D was 18.63%.
During the past 100 days, Voyager Therapeutics Inc’s (VYGR) raw stochastic average was set at 18.81%, which indicates a significant increase from 1.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.22 in the past 14 days, which was higher than the 0.22 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.18, while its 200-day Moving Average is $4.54. Nevertheless, the first resistance level for the watch stands at $3.10 in the near term. At $3.25, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.32. If the price goes on to break the first support level at $2.88, it is likely to go to the next support level at $2.81. Assuming the price breaks the second support level, the third support level stands at $2.66.
Voyager Therapeutics Inc (NASDAQ: VYGR) Key Stats
There are currently 55,336K shares outstanding in the company with a market cap of 163.80 million. Presently, the company’s annual sales total 80,000 K according to its annual income of -65,000 K. Last quarter, the company’s sales amounted to 6,470 K and its income totaled -31,020 K.
